FRA, 9VC End of Day and Historical Stock Data []

The worlds #1 website for end of day & historical stock data

wide range of exchanges, data formats, tools and services

APINEW HISTORICAL DATA SYMBOL LISTS MEMBERSHIP REGISTER LOG IN

FRA, 9VC: ATAI LIFE SCIENCES BV EO1

03 Sep 2025

LAST: 3.933	CHANGE: 0.23	OPEN: 3.901	HIGH: 3.933	ASK: 0.000	VOLUME: 8
LAST: 3.933	CHG(%): 6.30	PREV: 3.700	LOW: 3.901	BID: 0.000

CHART

Period:

RECENT END OF DAY PRICES

Date	Open	High	Low	Close	Volume
03 Sep 25	3.901	3.933	3.901	3.933	8
02 Sep 25	3.746	3.746	3.700	3.700	250
01 Sep 25	3.832	4.112	3.832	4.110	3.1K
29 Aug 25	3.926	3.926	3.926	3.926	10.1K
28 Aug 25	4.186	4.245	3.893	3.893	10.1K
27 Aug 25	4.200	4.200	4.040	4.040	527
26 Aug 25	3.880	4.250	3.880	4.200	470
25 Aug 25	3.852	3.852	3.852	3.852	2.3K
22 Aug 25	3.702	3.984	3.702	3.900	2.3K
21 Aug 25	3.329	3.700	3.329	3.700	100

COMPANY PROFILE

Name:	ATAI LIFE SCIENCES BV EO1
About:	Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia; and ELE-101, a serotonergic psychedelic in Phase 2a trial for the treatment of major depressive disorder. It is also developing VLS-01, an oral transmucosal film formulation of N,N-Dimethyltryptamine in Phase 2 clinical study to treat TRD; EMP-01, an oral formulation of R-3,4-methylenedioxy-methamphetamine that is in Phase 2 clinical study for social anxiety disorder; and EGX-A & EGX-B, which are non-hallucinogenic 5-HT2A receptor agonists in preclinical studies for TRD. In addition, the company offers COMP360 for psilocybin therapy; and GRX-917 for the treatment of anxiety, depression, and various neurological disorders. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.
Sector:	Healthcare
Industry:	Biotechnology
Address:	Wallstraße 16, Berlin, Germany, 10179
Website:	https://atai.com
ISIN:	NL0015000DX5

SYMBOL HISTORY

Purchase End of Day History
for this symbol from Jan 01, 0001

Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

Exchange:

Format:

Period:

Zip file

Symbol:

Start Date:

End Date:

TECHNICAL INDICATORS

MA5:	3.91
MA10:	3.93
MA20:	3.68
MA50:	3.10
MA100:	2.37
MA200:	1.93
STO9:	42.36
STO14:	67.18
RSI14:	57.81
WPR14:	-29.15
MTM14:	0.65
ROC14:	0.20
ATR:	0.23
Week High:	4.25
Week Low:	3.70
Month High:	4.25
Month Low:	3.24
Year High:	4.25
Year Low:	0.95
Volatility:	47.00